Kurt Briner is an independent consultant to pharmaceutical and biotechnology companies. He has over 30 years of experience in the pharmaceutical industry. Mr Briner is the former President and Chief Executive Officer of Sanofi Pharma S.A. in Paris, France, a position he held from 1988 until his retirement in 2000.

Mr. Briner was a long time director of Novo Nordisk and is an active Board member of Progenics Pharmaceuticals Inc. (USA) and Galenica S.A. (Switzerland). Mr. Briner holds a Diploma of the Commercial Schools of Basel and Lausanne, Switzerland.

William Camp joins BioAmber as the Naxos representative to the board.  Bill has over 20 years experience at Archer Daniels Midland Company (ADM), in a variety of management positions until he retired in December 2007 from his position as Executive Vice President and Vice President, Asia Strategy.  He was also an Executive Vice President, Processing from 2004 to August 2007.  Bill has significant experience in logistics and supply chain management.  He has been an independent director of Tate & Lyle PLC since 2010 and was a director of Wilmar International, Ltd. from 2005 to 2007.

Heinz Haller joins BioAmber as an independent board member with over 25 years of experience in the chemical industry. Heinz is Executive Vice President and Chief Commercial Officer of The Dow Chemical Company, responsible for Marketing and Sales worldwide,  Dow AgroSciences, Asia Pacific, Latin America, and he is the chairman of the board of Dow Kokam, a lithium ion battery JV with Townsend Ventures. He also sits on the board of Advanced Electrolytes, a JV between Dow and Ube Industries of Japan and serves on the board of Dow Corning,  a  JV  between  Dow and  Corning, as the lead director for Dow.  Heinz is a member of Dow’s Executive Leadership Committee and co‐chairs the Growth and Innovation Team with the CTO of Dow. Prior to his present responsibilities he was responsible for the Performance Materials Division of DOW. Heinz is a former CEO of OMYA/Pluess-­‐Stauffer, a privately held company active in chemical distribution and the world’s largest calcium carbonate mining company.  Heinz is a former CEO of Red Bull Sauber AG and Sauber Petronas Engineering AG, and a former Managing Director of Allianz Capital Partners GmbH.

Jean-François Huc is BioAmber’s CEO. Prior to BioAmber, he was the Chief Operating Officer of Diversified Natural Products (DNP), where oversaw the spin off of the succinic acid assets, at which time he stepped down from DNP to become President and CEO of BioAmber.  Prior to DNP Mr. Huc was CEO of TGN Biotech, a company producing recombinant proteins in transgenic animals.  Prior to TGN, he was the founder and CEO of MedExact, a startup offering web-based promotional services to pharmaceutical companies in the US and France.  Mr. Huc is a former Vice President of Alliance Management for Sanofi-Synthelabo, based in Paris, where he managed the company's global strategic alliances. Prior to Sanofi, he was a Partner with Arthur D. Little, a management consulting firm and Director of its French healthcare practice.   Mr. Huc has an M.B.A. from York University in Toronto and an undergraduate degree in biochemistry from the University of Western Ontario.

Taro Inaba is General Manager with Cleantech and Healthcare Investment Department, Principal Investment Division of Mitsui & Co., Ltd. being responsible for Mitsui's principal investments. He has 20 years experience in business development, investment and management in life science and chemical industries.

Prior to this, Taro was President & CEO at Mitsui & Co. Venture Partners, Inc. (Mitsui Ventures) in Menlo Park, California being responsible for managing Mitsui's venture investment funds. At Mitsui Ventures, where he spent more than 10 years since 2000, he has focused on biopharma and cleantech opportunities with his special effort to establish companies with the intellectual properties developed by Japanese institutions with their development and commercialization take place in the United States. He served as an investor and director in over 15 new companies in the portfolio. Taro currently serves on the Board of Actimis Pharmaceuticals, Boston Biomedical, Hutchison Medipharma, and BioAmber.

He joined Mitsui in 1991 and worked for the firm's chemical business units responsible for the business development of multiple organic chemical products from 1991 to 1999. Taro received a MBA from European University in Lisbon and a Bachelor in Engineering in Polymer Chemistry from Kyoto University. He is a CFA charter holder.

Raymond Land joins BioAmber as an independent board member and Chair of the audit committee.  Ray has over 35 years financial experience and has been the Chief Financial Officer of four publicly traded companies: Clarient (CLRT), Orchid Cellmark (ORCH), Genencor (GCOR) and West Pharmaceutical Services (WST).  He was formerly the Vice President-­‐Corporate Controller and then a Vice–President General Manager of Campbell Soup Co.’s Frozen Food Division.  Ray has also been the audit committee chair for several private and public companies. Ray has extensive experience in assisting start-­‐ups put in place the financial organizations, systems and procedures needed to manage rapid growth and ensure compliance. Ray is a certified public accountant and spent 9 years at Coopers & Lybrand.

Denis Lucquin is a Managing Partner and Chairman who specialises in life sciences, and also, more recently, in cleantech investments. He joined Sofinnova in 1991. Denis began his career in academic research. For five years, he was in charge of the technology transfer department at the Institut National de la Recherche Agronomique (INRA), France's agricultural research institute.

In 1989, he joined the venture capital industry as director of investments at Innolion (Crédit Lyonnais). He carried out many investments in Europe such as Nicox, Oxford Glycosciences, Oxford Molecular, PPL Therapeutics, Conjuchem, Exonhit, IDM, Innate Pharma and Ablynx (all of which successfully went public) and Crop Design, Cerenis, Novexel and Noxxon. He actively supports all of these companies and acts or has acted as a board member for most of them. He is also a founder of Association France Biotech.

Mr. Lucquin is a graduate in engineering from Ecole Polytechnique and Ecole du Génie Rural des Eaux et Forêts. He also has a degree in Innovation Management from the Université de Paris-Dauphine.

In 2007 Mr. Nogueira was appointed Chairman of the Board of Management of Petroflex S.A., one of South America’s leading manufacturers of synthetic rubber, which was acquired by LANXESS at the end of 2007.  Jorge Nogueira has headed the Functional Chemicals Business Unit at LANXESS since August 1, 2008.